NCNA
NuCanaNCNA
NCNA
About: NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Employees: 22
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.31% less ownership
Funds ownership: 0.79% [Q4 2024] → 0.48% (-0.31%) [Q1 2025]
40% less funds holding
Funds holding: 20 [Q4 2024] → 12 (-8) [Q1 2025]
55% less capital invested
Capital invested by funds: $532K [Q4 2024] → $238K (-$294K) [Q1 2025]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Research analyst outlook
We haven’t received any recent analyst ratings for NCNA.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
NuCana Reports First Quarter 2025 Financial Results and Provides Business Update
Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma
Neutral
GlobeNewsWire
2 months ago
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025
Neutral
Business Wire
4 months ago
Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.
Neutral
GlobeNewsWire
6 months ago
NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024
Neutral
GlobeNewsWire
7 months ago
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Pembrolizumab
Positive
GuruFocus
8 months ago
Baillie Gifford's Strategic Acquisition of NuCana PLC Shares
On September 1, 2024, Baillie Gifford (Trades, Portfolio), a prominent investment management firm, expanded its portfolio by acquiring 917,600 shares of NuCana PLC, a UK-based biopharmaceutical company. This transaction, executed at a price of $3.66 per share, marks a significant addition to Baillie Gifford (Trades, Portfolio)'s holdings, reflecting a strategic move within the biotechnology sector.
Neutral
GlobeNewsWire
8 months ago
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738's composition of matter. This patent (US12,054,510) is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide. NUC-7738 is a novel anti-cancer agent currently in a Phase 2 clinical study in combination with pembrolizumab in PD-1 inhibitor resistant melanoma patients, for which NuCana presented encouraging data at the ESMO Congress 2024 earlier this month.
Positive
Zacks Investment Research
8 months ago
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.
Neutral
GlobeNewsWire
9 months ago
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile
Neutral
GlobeNewsWire
9 months ago
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee
Charts implemented using Lightweight Charts™